Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 99 people across two groups: 48 with pancreatic neuroendocrine tumours (panNET) and 51 with midgut neuroendocrine tumours (midgut NET). The trial was measuring how long participants went without their disease progressing (getting worse) while receiving a medicine called lanreotide Autogel® 120 mg, given by injection every 14 days. Tumour changes were checked every 12 weeks using CT or MRI scans. Of those who started, 43 in the panNET group and 46 in the midgut NET group completed the study. The reported data shows that the median time without disease progression (meaning half of participants reached this point or beyond before progression or death) was 5.6 months for the panNET group and 8.3 months for the midgut NET group. For the secondary measure of time specifically to progression (not counting deaths), the figures were 5.6 months and 8.7 months respectively. Looking at the proportion of participants still alive and progression-free over time, the reported data shows this declined gradually in both groups across the follow-up period. For overall survival, the median could not be calculated for either group, meaning the data was not mature enough at the time of reporting to produce that figure. No participant in either group showed a complete or partial tumour shrinkage response (objective response rate of 0%) at most time points, though small percentages in the midgut NET group were reported at later time points. The reported data shows that the proportion of participants whose disease was controlled (tumours shrinking or staying stable) was 43.8% in the panNET group and 58.8% in the midgut NET group at week 24, dropping to 22.9% and 33.3% respectively by week 48. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Pancreatic Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a neuroendocrine tumour (NET) of the pancreas or the middle part of the small intestine (midgut), confirmed by a tissue sample, that is either grade 1 or grade 2, and has spread to other parts of the body or cannot be removed by surgery.
- Your tumour has a low growth rate, measured by a test called Ki67, showing 20% or less.
- Your tumour has a specific protein on its surface called somatostatin receptor type 2, confirmed by a scan or test.
- Your tumour has been shown to be getting worse (progressing) while you have been receiving a standard treatment called lanreotide Autogel® 120 mg, given every 28 days for at least 24 weeks, as confirmed by an independent medical review.
Who may not be able to join:
- Your NET is grade 3 (faster growing) or has been progressing very quickly within the last 12 weeks.
- Your NET started in a part of the body other than the pancreas or the midgut (middle small intestine).
- You have previously received any cancer treatment for your NET other than lanreotide Autogel® 120 mg every 28 days — although prior use of a similar medicine called Octreotide (at a standard dose, stopped for a reason other than the tumour getting worse) may be acceptable (confirm with trial site).
- You currently have gallstones causing symptoms, or you have a history of gallstones and have not had your gallbladder removed.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Median Progression Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.